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CASE PRESENTATION
A 39-year-old Caucasian G4P2 woman at 27 weeks
gestation was admitted to the hospital with newly
diagnosed dilated cardiomyopathy and non-sustained
ventricular tachycardia. Her urine output was 2.5–7 l/24 h.
Serum magnesium levels were low despite repletion with
up to 160 mEq of oral and i.v. magnesium daily. She had
completed two prior pregnancies uneventfully, but
complained of thirst, polyuria, and nocturia predating the
current pregnancy by approximately 2 years. There was no
history of lithium or diuretic use, head trauma, or
neurological deficits. Past medical and family history was
otherwise unremarkable. Physical examination revealed
a well-appearing pregnant woman. Blood pressure was
80/60, jugular venous pressure was flat, and there was
minimal peripheral edema. Laboratory values are shown
in Table 1. Responses to 1-deamino-8-arginine vasopressin
(dDAVP) and a water-deprivation test are shown in Figures
1 and 2.
DIAGNOSIS
Decreased osmotic threshold for sensation of thirst, un-
masked by pregnancy and exacerbated by a high osmolar
load.
CLINICAL FOLLOW-UP
Serum magnesium levels remained stable and urinary
collections suggested that the majority of exogenous
magnesium supplementation was being excreted in the urine.
This was consistent with normal physiologic responses of
pregnancy and further suggested that the persistent osmotic
losses were exacerbating the polyuria. Magnesium supple-
mentation was tapered and ultimately discontinued, and
serum magnesium levels remained in the 1.5–1.8 mg/dl range:
reference range 1.8–2.5 mg/dl (0.6–0.7 mmol/l: reference
range 0.7–1.0). Urine output decreased to 2–5 l/24 h but
remained high and the patient continued to complain of
severe thirst.
The possibility of a baseline or pregnancy-induced
diabetes insipidus (DI) was considered. The patient was
challenged with ddAVP and a water deprivation test was
performed (Figures 1 and 2). In both tests, the patient
demonstrated an ability to concentrate the urine to
X600 mOsm/kg. These results confirmed the presence of
intact central production of and nephrogenic response to
vasopressin (AVP) and ruled out the possibility of clinically
significant DI. Conversely, the patient complained of extreme
thirst at serum osmolalities p285 mOsm/kg, which con-
firmed the suspicion of a reduced osmotic threshold for
thirst. Following the water deprivation test, the patient was
allowed ad-lib access to water. Hospitalization continued
without any evidence of hypernatremia or volume depletion.
Labor was induced and a healthy male infant was delivered
uneventfully at 35 weeks. At 2 weeks post-partum, the patient
continued to complain of thirst and palpitations but was
otherwise well. Blood pressure was 90/50, and JVP flat.
Laboratory values were as follows: serum sodium 140 mmol/l:
reference range 136–142 mmol/l; potassium 4 mmol/l: reference
range 3.5–5 mmol/l; chloride 107 mmol/l: reference range
98–108 mmol/l; bicarbonate 23 mmol/l: reference range 23–32
mmol/l; calcium 8.4 mg/dl: reference range 8.8–10.5 mg/dl
(2.1 mmol/l: reference range 2.2–2.6 mmol/l); magnesium
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2.0 mg/dl: reference range 1.8–2.5 mg/dl (0.8 mmol/l: refer-
ence range 0.72–1.0 mmol/l); albumin 3.9 mg/dl: reference
range 3.7–5.4 g/dl (39 g/l: reference range 37–54 g/l).
DISCUSSION
The syndrome of DI is characterized by polyuria and
polydipsia, and is associated with intense thirst due to the
loss of concentrating ability by the kidney. If the patient has
free access to water, the rise in the serum osmolality and
serum sodium is often mitigated by the thirst sensation, but
the urinary loss of water is obligate. The cause of the
syndrome is due either to impaired secretion of AVP by the
Table 1 | Laboratory values
Value (reference range)
Serum/blood
Sodium 136 mmol/l (136–142)
Potassium 4.0 mmol/l (3.5–5.0)
Chloride 105 mmol/l (98–108)
Bicarbonate 27 mmol/l (23–32)
Glucose 74 mg/dl (54–118) (4.1 mmol/l (3.0–6.6))
Urea nitrogen 8 mg/dl (9–25) (2.9 mmol/l (3.2–8.9))
Creatinine 0.5 mg/dl (0.7–1.3) (44.2 mmol/l (62–115))
Calcium 8.0 mg/dl (8.8–10.5) (2.0 mmol/l (2.2–2.6))
Ionized calcium 1.14 mmol/l (1.13–1.32)
Magnesium 1.6 mg/dl (1.8–2.5) (0.7 mmol/l (0.78–1.2))
Albumin 3.4 g/dl (3.7–5.4) (34 g/l(37–54))
Osmolality 283 mOsm/kg (278–297)
Antidiuretic hormone oassay (0.0–4.7)
Diuretic screen Negative
Urine
Urinalysis pH 5, specific gravity 1.008, neg blood,
protein, glucose
Osmolality 247 mOsm/kg (390–1093)
24 h volume 5575 ml (600–1600)
24 h creatinine 1578 mg (800–1800) (139495 mmol
(70 720–159 120))
24 h sodium 156 mmol (75–200)
24 h potassium 127 mmol (40–80)
24 h calcium 502 mmol (50–400)
24 h magnesium 797 mg (121–243) (32.8 mmol (5.0–10))
24 h phosphate 931 mg (500–1200) (9.8 mmol (5.3–12))
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Figure 1 | Response to dDAVP.
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Figure 2 | Response to H2O deprivation.
Table 2 | Osmoregulation in normal pregnancy
Plasma sodium Decreased by approximately 5 mEq/l
Plasma osmolarity Decreased by approximately 10 mOsm/kg
AVP 1–8 pg/ml (unchanged from nongravid state)
Metabolic clearance
of AVP
4-fold increase
24 h urine volume Unchanged from nongravid state
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pituitary gland (central DI) or to an impaired renal response
to AVP (nephrogenic DI). AVP activates the V2 receptor on
the collecting duct cells in the kidney to stimulate water
absorption.
The first reports of transient polyuria and polydipsia
associated with pregnancy appeared over 60 years ago,1,2 and
it has since been estimated that DI complicates approximately
1/300 000 pregnancies.3 The occurrence of DI during
pregnancy is not surprising, given the profound alterations
in the regulation of plasma osmolality and thirst that occur
during normal gestation (Table 2). Both serum sodium and
plasma osmolality are known to drop by approximately
5 mEq/l and 10 mOsm/kg, respectively, during pregnancy.4
Similarly, in both rats and humans, the thresholds for
vasopressin (AVP) release and thirst are reset in the normal
gravid state. Human chorionic gonadotrophin may play a
role in these osmoregulatory changes,5 but placental
production of vasopressinase plays an important role during
the third trimester.6 Davison et al.7 demonstrated that vaso-
pressinase levels were measurable starting at week 10 of
gestation and reached peak levels by 22–24 weeks. At 22–24
weeks of normal pregnancy, the metabolic clearance of AVP
increases fourfold. Plasma levels of AVP remain in the normal
range, indicating that an increased compensatory secretion
of AVP by the pituitary gland matches the rate of its
degradation.
These changes in thirst, AVP release and AVP metabolism
typically result in a self-limited decrease of approximately
10 mOsm/kg in serum osmolarity by the third trimester.
However, in some cases, the changes can be profound. Barron
et al.8 published a report of previously healthy women
developing polyuria in the immediate puerperium unrespon-
sive to large amounts of exogenously administered AVP.
Because all symptoms resolved later on in the post-partum
period, the authors termed the condition ‘transient vaso-
pressin-resistant DI of pregnancy’, recognizing that increased
destruction of AVP may have occurred, rather than simply
increased renal resistance to the hormone. Durr et al.9 later
reported a study on a patient with significant polyuria (up to
25 l/day) and hypernatremia in the puerperium who failed to
concentrate her urine after administration of AVP. However,
her urine osmolality increased to 800 mOsm/kg when
dDAVP, an endogenous AVP analogue resistant to inactiva-
tion by vasopressinase that selectively activates the non-
pressor V2 vasopressor receptor, was administered.
7 High
levels of circulating vasopressinase in the post-partum period
suggested increased destruction of AVP by placental vaso-
pressinase, although alterations in the kinetics of the enzyme
has been offered as another explanation.4
Another disorder has been described where women with
partial central DI, asymptomatic when nongravid, manifest
polyuria after midpregnancy, coincident with the normal
four-fold increase in AVP catabolism. This disorder remits
postpartum.10 In addition, Iwasaki et al.11 studied two
women in whom overt polyuria and polydipsia developed
during the third trimester of pregnancy and disappeared
after delivery. They reported not only an increase in the
degradation of vasopressin during pregnancy but also an
increased resistance at the level of the kidney to the action of
AVP. They concluded that pregnancy may unmask subclinical
forms of both nephrogenic and neurogenic DI. This
exacerbation may result from both increased vasopressinase
activity and diminished renal responsiveness to AVP.
Regardless of its cause, DI during pregnancy is suggested
by the output of large volumes (42.5 l/day) of hypotonic
urine. If urine osmolarity is Xserum osmolarity, osmotic
diuresis should be considered in the differential. A water
deprivation test should be conducted to confirm the
diagnosis of DI. The failure to decrease urinary volume or
to increase urine osmolarity above 600 mOsm/l when serum
osmolarity exceeds 295–300 mOsm/kg confirms the diagnosis
of DI. Central DI can be distinguished from nephrogenic DI
by the absence of biologically active AVP in vivo, although
care must be taken in measuring AVP levels, as vasopressinase
is extremely active in vitro,4 which may confuse the diagnosis.
DI of pregnancy induced by placental vasopressinase is
confirmed when the urine is concentrated in response to
dDAVP but not in response to AVP.12 When DI of pregnancy
is diagnosed, limited data suggest that dDAVP can be used
safely to control urine output.13 Careful attention should be
paid to serum osomolarity after administration of general
anesthesia when access to water may be restricted.
In this case, the normal responses to both dDAVP and
water deprivation ruled out both nephrogenic and central
DI and suggested a more unusual cause. Polydipsia,
likely exacerbated by pregnancy-induced resetting of the
thirst threshold, was ultimately felt to be the etiology and the
patient was treated simply by allowing free access to water.
Several studies have reported hypomagnesemia associated
with pregnancy.14–18 Standley et al.19 followed 22 healthy
women throughout their pregnancies and found that both
total and ionized serum magnesium levels decreased with
increasing gestational age, while sodium, potassium, total
and ionized calcium levels remained unchanged. Handwerker
et al.16 noted that healthy women in the latter stages
of pregnancy had lower levels of both total and ionized
magnesium compared to women in their first trimester.
Many hypotheses have been proposed as a cause for this
gestational ‘hypomagnesemia’, including hemodilution,19
extracellular volume expansion causing reduced magnesium
resorption,20 and fetal consumption of magnesium.15
CLINICAL PERSPECTIVE AND CONCLUSIONS
Nephrologists caring for pregnant patients must be aware of
the normal physiologic changes in the handling of water and
electrolytes that occur during gestation. Osmotic disorders
during pregnancy are simple to both diagnose and treat with
water deprivation tests and vasopressin challenges as the
cornerstones of diagnosis. Patients with a reset threshold for
thirst can be reassured, while dDAVP can be administered
to patients with vasopressinase-induced DI. Serum sodium
should be carefully monitored when access to water is
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restricted as ongoing water losses in this setting of can be life-
threatening if unrecognized. Finally, a low serum magnesium
level is not a cause for alarm as this appears to be physiologic
in the setting of pregnancy.
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